metaMe Health Announces First Subject Enrolled in Pivotal Study of a Digital Therapeutic for Treatment of IBS

CHICAGO (October 31, 2019) — metaMe Health, Inc., a Chicago-based prescription digital therapeutics company committed to the treatment of gastrointestinal (GI) conditions such as Irritable Bowel Syndrome (IBS), today announced that the first subject has enrolled in a pivotal study to evaluate the efficacy and safety of an all-digital, self-administered behavioral therapy for the treatment of adult subjects with symptomatic IBS. This trial is a randomized, controlled, parallel-group study that will enroll subjects from across the United States.